Dynavax Technologies (NASDAQ:DVAX) Sees Strong Trading Volume – Here’s What Happened

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) saw unusually-strong trading volume on Monday . Approximately 4,646,685 shares changed hands during mid-day trading, an increase of 122% from the previous session’s volume of 2,096,736 shares.The stock last traded at $15.3750 and had previously closed at $15.38.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on DVAX shares. Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday. William Blair downgraded Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.33.

Dynavax Technologies Stock Up 0.1%

The company has a market cap of $1.81 billion, a P/E ratio of -41.57 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The business’s fifty day moving average is $11.31 and its two-hundred day moving average is $10.65.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.07. The business had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. Equities analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Insider Transactions at Dynavax Technologies

In other Dynavax Technologies news, COO David F. Novack sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total transaction of $464,700.00. Following the transaction, the chief operating officer owned 111,451 shares of the company’s stock, valued at approximately $1,726,375.99. This trade represents a 21.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.98% of the stock is currently owned by insiders.

Institutional Trading of Dynavax Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. raised its position in shares of Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,710 shares in the last quarter. LSV Asset Management bought a new stake in Dynavax Technologies during the third quarter valued at about $89,000. Osaic Holdings Inc. grew its stake in Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares during the last quarter. Callan Family Office LLC bought a new position in Dynavax Technologies in the second quarter worth about $107,000. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $109,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.